Perindopril

Perindopril

Clinical data
Trade names	Coversyl, Coversum, Preterax, Aceon
AHFS/Drugs.com	Monograph
MedlinePlus	a602017
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
ATC code	C09AA04 (WHO) C09BA04 (WHO) (with diuretics) C09BB04 (WHO) (with amlodipine)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	24%
Protein binding	20%
Metabolism	Renal
Biological half-life	1–17 hours for perindoprilat (active metabolite)
Identifiers
IUPAC name (2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
CAS Number	82834-16-0 N
PubChem (CID)	107807
IUPHAR/BPS	6367
DrugBank	DB00790 Y
ChemSpider	96956 Y
UNII	1964X464OJ N
KEGG	D03753 Y
ChEBI	CHEBI:8024 Y
ChEMBL	CHEMBL1581 Y
ECHA InfoCard	100.124.027
Chemical and physical data
Formula	C19H32N2O5
Molar mass	368.468 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@H]12)C)CCC
InChI InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1 Y Key:IPVQLZZIHOAWMC-QXKUPLGCSA-N Y
NY (what is this?)

Perindopril is a long-acting ACE inhibitor used to treat high blood pressure, heart failure, or stable coronary artery disease in form of perindopril arginine (trade names include Coversyl, Coversum) or perindopril erbumine (Aceon). According to the Australian government's Pharmaceutical Benefits Scheme website, based on data provided to the Australian Department of Health and Aging by the manufacturer, perindopril arginine and perindopril erbumine are therapeutically equivalent and may be interchanged without differences in clinical effect. However, the dose prescribed to achieve the same effect differs due to different molecular weights for the two forms.

Perindopril shares the indications of ACE inhibitors as a class, including essential hypertension, stable coronary artery disease (reduction of risk of cardiac events in patients with a history of myocardial infarction and/or revascularization) and treatment of symptomatic heart disease or failure. In addition, the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) found that perindopril reduces the risk of stroke in both hypertensive and nonhypertensive individuals with a history of stroke or transient ischemic attack.

The Anglo-Scandinavian Cardiac Outcomes Trial showed the benefits of taking the two drugs perindopril and amlodipine together. About 9000 British patients aged 40 to 79 were involved in the five-year trial. Half were given the new drug combination; the rest were given traditional drugs. Perindopril and amlodipine were found to be so effective, the trial was stopped early so all patients could receive the combination.

Each tablet contains 2, 4, or 8 mg of the tert-butylamine salt of perindopril. Perindopril is also available under the trade name Coversyl Plus, containing 4 mg of perindopril combined with 1.25 mg indapamide.

In Australia, each tablet contains 2.5, 5, or 10 mg of perindopril arginine. Perindopril is also available under the trade name Coversyl Plus, containing 5 mg of perindopril arginine combined with 1.25 mg indapamide and Coversyl Plus LD, containing 2.5 mg of perindopril arginine combined with 0.625 mg indapamide.